Study S001106

Combined Active Treatment in Type 2 Diabetes With NASH

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04639414
Acronym: COMBAT_T2_NASH
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 192
Start: 2021-03-26
Primary completion: 2025-01-31
Lead sponsor: German Diabetes Center
Conditions: Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: DRUG:Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector; DRUG:Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide; DRUG:Placebo matching empagliflozin and placebo pen injector matching semaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2019-001987-31; NIH:2019

Registered primary outcomes

Histological resolution of NASH without worsening of fibrosis [from baseline to 48 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0040528	From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis Manik Aggarwal, Clinical Liver Disease	2023	Other	PMID 36938314 DOI	cites ClinicalTrials.gov:NCT04639414